A recent study provides critical insights into the reliability and robustness of patient-derived organoids as a clinical model of pancreatic cancer. The findings reveal that organoids’ gene expression and drug responses are not affected by the brand of extracellular matrix used in the cell culture. However, one commercial product did increase the growth rate of pancreatic tumor organoids, making it particularly well-suited for the fast pace of pancreatic cancer treatment protocols.